Navigation Links
Chimerix's Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
Date:12/13/2010

DURHAM, N.C., Dec. 13, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile. In addition, results from a series of preclinical studies showed that CMX157 exhibited highly potent in vitro activity against human immunodeficiency virus (HIV), including HIV strains resistant to current therapies, and potent in vitro activity against xenotropic murine leukemia virus-related virus (XMRV), a blood-borne retrovirus recently associated with chronic fatigue syndrome (CFS).CMX157 clinical and preclinical findings were presented in an oral abstract, titled "CMX157 (HexadecyloxypropylTenofovir), a Clinical Stage Antiretroviral with In Vitro Activity against HIV and XMRV" at the HIV DART™ 2010 Frontiers in Drug Development for Antiretroviral Therapies conference.  

"CMX157's promising safety profile and efficient conversion to the active drug in peripheral blood mononuclear cells, coupled with the potent in vitro antiviral activity across diverse drug-resistant strains of HIV, indicate that this compound may directly address the limitations of current HIV therapies," said Randall Lanier, Ph.D., Senior Director of Virology of Chimerix.  "We are also excited about CMX157's in vitro antiviral activity against XMRV, a retrovirus recently associated with chronic fatigue syndrome."

"Our CMX001 and CMX157 programs are producing compelling clinical and preclinical evidence of how Chimerix's PIM Conjugate Technology transforms the way compounds are absorbed, distributed, metabolized and excreted, creating new agents with improved antiviral action and reduced toxicities.  The promising clinical and preclinical data being reported for CMX157 strengthen our commitment to advancing this novel antiviral for
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
2. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
8. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... in the 2014 Morgan Stanley Global Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Peptide Cancer Therapeutics Market & Pipeline Insight ... The conventional methods developed to prevent and eradicate the ... treatment. These methods are confined to low specificity, safety ... researchers to look for a better solution. It has ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... Sept. 23, 2011 A pharmaceutical company,s marketing strategy ... introducing a new brand in a space where the ... two-thirds of companies, the most frequent changes require shifting ... activities, such as professional relations, promotional literature, sampling, and ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Company intends to release its third quarter 2011 financial results ... the U.S. financial markets.  The Company will also host a ... November 1, 2011 to discuss its financial results and provide ...
Cached Medicine Technology:Pharmaceutical Marketing Strategy Balances Support Between New & Established Products in the Same Indication 2Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings 2
(Date:8/30/2014)... Jake W., 18, is completing his high ... Back2Basics Outdoor Adventures transition program known as Beyond the ... I can actually start on a real career path,” said ... done.” , He has six months of sobriety under his ... choose to continue on to the Beyond the Basics transition ...
(Date:8/30/2014)... 2014 “In 2013, a vehicle crash occurred ... says in a recently released article on 2013 Washington ... in an auto accident every 12 minutes, and a motorcyclist ... “Based on the 2013 statistics, between now and this same ... The threat of an auto accident is real and impending ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 Zensah®, the ... Camo Compression Leg Sleeve . The camo sleeves are ... Leg Sleeve collection. The camo line includes classic colors ... and magenta. , Known as tibial stress syndrome, shin ... of the lower leg. Swollen and irritated muscles, stress fractures, ...
(Date:8/30/2014)... Barton Associates, an industry leading physician, ... , announces a new office location in Keene, NH, ... headquartered in Peabody, MA, with additional staffing centers in ... Jupiter, FL. , Barton Associates made the decision to ... crisis affecting the United States, a crisis that will ...
(Date:8/30/2014)... August 30, 2014 What challenges exist ... are the latest trends, concerns, and considerations? Sports ... Ken Pendleton recently spoke with Woody Wommack, Southeast Football ... current issues in football recruiting. Notably, Wommack spoke ... athletes, changes that he thinks are coming as a ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... Now Available on Online Community to Facilitate Collaboration ... BEACH, Fla., May 8 With a growing ... short weeks since launch, e-Zassi.com has added an ... participants involved in the discovery, development and commercialization ...
... York City Raises Money for STAR (TM) ... Charcot-Marie-Tooth Association,s second annual "Honor a Star. Be a Star." ... achievement raised a record amount of over $350,000 at the ... Proceeds earned from event sponsorship, ticket sales and auction items ...
... One Global Health Threat"WASHINGTON, May 8 Today, HIV ... of Human Virology at the University of Maryland ... of the World Foundation for AIDS Research and Prevention, ... six objectives to end the HIV/AIDS pandemic. They ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide announced today it filed with the,Securities ... 20-F that included,audited financial statements for the year ... Annual Report on Form 20-F is available online,at ...
... part of the Elekta Group, has been selected to ... the 2009 American Society of Clinical Oncology,s (ASCO) Annual ... County Convention Center, in Orlando, Florida. Chosen according to ... third consecutive year Impac Software ...
... May 8, 2009 AMERIGROUP Corporation (NYSE: ... the Deutsche Bank 34th Annual Healthcare Conference on May 18 ... Monday, May 18 at 2:25pm Eastern Time, can be accessed ... the investors, page. A replay will be available for 30 ...
Cached Medicine News:Health News:New Advanced Search and Matching Function Drives e-Zassi.com's Enhanced Functionality 2Health News:Charcot-Marie-Tooth Association's 'Honor a Star. Be a Star.' Gala Generates Over $350,000 for CMT Research 2Health News:A Global Call to Action From HIV Co-Discoverers Robert Gallo and Luc Montagnier 2Health News:A Global Call to Action From HIV Co-Discoverers Robert Gallo and Luc Montagnier 3Health News:Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission 2Health News:Impac Software Selected to Present at the Electronic Health Records Lab During 2009 ASCO Annual Meeting 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: